Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
Status:
Withdrawn
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to found out if the drug IDH305 is safe and effective in
subjects with IDH1 mutant grade II or III glioma that has progressed after observation or
radiation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health